What's new? Log in Free sign up

MAIA Biotechnology (MAIA)

Company Profile

Company profile

Ticker

MAIA

Exchange

Website

www.maiabiotech.com

CEO

Dr. Vlad Vitoc M.B.A., M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

GigCapital4, Inc.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

MAIA Biotechnology Australia Pty Ltd. ...

MAIA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Prospectus supplement for primary offering

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Quarterly report

12 Nov 24

$15.50 mm in equity / options / securities to be acquired, sold $2.44 mm, 21 investors

MAIA Biotechnology Announces $2.44 Million Private Placement

Regulation FD Disclosure

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

Latest ownership filings

View all

Ramiro Guerrero

STEVEN M CHAOUKI

Ramiro Guerrero

Financial summary

Financial statements Chart MAIA financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	8.69 mm	8.69 mm	8.69 mm	8.69 mm	8.69 mm	8.69 mm
Cash burn (monthly)	(no burn)	37.95 k	1.40 mm	1.62 mm	912.00 k	1.12 mm
Cash used (since last report)	n/a	106.93 k	3.93 mm	4.57 mm	2.57 mm	3.16 mm
Cash remaining	n/a	8.58 mm	4.76 mm	4.12 mm	6.12 mm	5.53 mm
Runway (months of cash)	n/a	226.2	3.4	2.5	6.7	4.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MAIA institutional ownership history Ownership history

11.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	1	+900.0%
Opened positions	9	0	NEW
Closed positions	0	3	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	465.92 mm	3.56 mm	+12987.5%
Total shares	1.69 mm	1.55 mm	+9.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Stan Smith	1.55 mm	$3.56 mm	0.0%
Bridgeway Capital Management	45.70 k	$156.29 mm	NEW
STT State Street	34.40 k	$117.65 mm	NEW
Verition Fund Management	15.37 k	$52.57 mm	NEW
Wealth Enhancement Advisory Services	14.80 k	$50.62 mm	NEW
Mather	12.06 k	$26.53 mm	NEW
Jane Street	11.93 k	$40.80 mm	NEW
MS Morgan Stanley	5.10 k	$17.43 mm	NEW
BAC Bank of America	137.00	$469.00 k	NEW
RY Royal Bank of Canada	86.00	$0.00	NEW

Largest transactions	Shares	Bought/sold	Change
Bridgeway Capital Management	45.70 k	+45.70 k	NEW
STT State Street	34.40 k	+34.40 k	NEW
Verition Fund Management	15.37 k	+15.37 k	NEW
Wealth Enhancement Advisory Services	14.80 k	+14.80 k	NEW
Mather	12.06 k	+12.06 k	NEW
Jane Street	11.93 k	+11.93 k	NEW
MS Morgan Stanley	5.10 k	+5.10 k	NEW
BAC Bank of America	137.00	+137.00	NEW
RY Royal Bank of Canada	86.00	+86.00	NEW
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MAIA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Dec 24	Ramiro Guerrero	Common Stock	Buy	Acquire P	No	No	1.872	53,418	100.00 k	514,970
13 Dec 24	Ramiro Guerrero	Warrants Common Stock	Buy	Acquire P	No	No	2.08	53,418	111.11 k	53,418
13 Dec 24	Stan Smith	Common Stock	Buy	Acquire P	Yes	No	1.872	25,000	46.80 k	1,130,060
13 Dec 24	Stan Smith	Warrants Common Stock	Buy	Acquire P	Yes	No	2.08	25,000	52.00 k	25,000
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Acquire G	Yes	No	2.5	41,253	103.13 k	41,253
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Dispose G	No	No	2.5	41,253	103.13 k	0
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Acquire G	Yes	No	2.5	41,253	103.13 k	41,253
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Dispose G	No	No	2.5	41,253	103.13 k	41,253
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Acquire G	Yes	No	2.5	41,254	103.14 k	41,254
5 Nov 24	Vlad Vitoc	Stock Options Common Stock	Gift	Dispose G	No	No	2.5	41,254	103.14 k	82,506

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Reported Earlier, MAIA Biotechnology Raises $950k In Private Placement Of 507,364 Common Shares At $1.872/Share

Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.08 per share, which price represents the greater of the book or market value of the

Reported Earlier, MAIA Biotechnology Secures $2.44M In Private Placement, Aiming To Fund Key Phase 2 THIO-101 Cancer Trial

The gross proceeds from the offering are expected to be approximately $2.44 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund

MAIA Biotechnology Announces Poster Presentation Of Novel THIO Prodrugs At ENA 2024 Symposium On Molecular Targets And Cancer Therapeutics

MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trialsMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted

Press releases

From Benzinga Pro

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that two of the Company's independent directors,

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the

MAIA Biotechnology Announces Private Placement of Approximately $950,000

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.